Login or sign up
For business

Targacept, inc.

3.9ยท 13 reviews
Average ratingAverage
3.9/ 5

Based on 13 reviews

531%
431%
338%
20%
10%
Ask AI

Ask AI about Targacept, inc.

Generated with AI from 13 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website โ€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Targacept, inc.

Find domain names, web hosting and online marketing for your website -- all in one place. Network Solutions helps businesses get online and grow online with domain name registration, web hosting and innovative online marketing services.

Targacept, Inc. is a leading biopharmaceutical company that specializes in the discovery and development of novel drugs for the treatment of central nervous system disorders. The company was founded in 1997 and is headquartered in Winston-Salem, North Carolina.

Targacept's mission is to improve the lives of patients suffering from debilitating neurological and psychiatric conditions by developing innovative therapies that target specific receptors in the brain. The company's research focuses on nicotinic receptors, which are involved in a wide range of physiological processes including learning, memory, attention, and mood regulation.

One of Targacept's most promising drug candidates is TC-5214, which has shown significant efficacy in treating major depressive disorder (MDD) in clinical trials. MDD affects millions of people worldwide and can be a debilitating condition that significantly impacts quality of life. TC-5214 works by modulating nicotinic receptors to enhance neurotransmitter release and improve mood.

In addition to its drug development programs, Targacept also collaborates with other pharmaceutical companies to develop new therapies for CNS disorders. The company has partnerships with AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and others.

Targacept has a strong track record of innovation and success in drug discovery. In 2009, the company received FDA approval for its first drug candidate - AZD3480 - which was licensed to AstraZeneca for further development. Targacept also has several other compounds in various stages of clinical development for indications such as Alzheimer's disease and schizophrenia.

The team at Targacept includes some of the world's leading experts on nicotinic receptors and CNS disorders. The company employs over 100 scientists who work tirelessly to discover new treatments for these devastating conditions.

In conclusion, Targacept is an innovative biopharmaceutical company that is dedicated to improving the lives of patients suffering from CNS disorders through cutting-edge research into nicotinic receptor modulation. With a strong pipeline of drug candidates and partnerships with major pharmaceutical companies around the world, Targacept is well-positioned to continue making significant contributions to this important field for years to come.

Categories
Biotechnology